During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 3 | 0 | 1 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 4 | 2 | 3 | 0 | 1 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positive shift, the current average has risen by 14.52% from the previous average price target of $101.60.
Investigating Analyst Ratings: An Elaborate Study
The standing of Blueprint Medicines among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $125.00 | $125.00 |
| Sudan Loganathan | Stephens & Co. | Announces | Overweight | $140.00 | - |
| Andrew Berens | Leerink Partners | Raises | Market Perform | $97.00 | $50.00 |
| Terence Flynn | Goldman Sachs | Raises | Buy | $168.00 | $121.00 |
| David Lebowitz | Citigroup | Raises | Sell | $76.00 | $65.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $135.00 | $125.00 |
| Reni Benjamin | JMP Securities | Raises | Market Outperform | $125.00 | $114.00 |
| Peter Lawson | Barclays | Raises | Equal-Weight | $75.00 | $70.00 |
| Christopher Raymond | Piper Sandler | Raises | Neutral | $104.00 | $78.00 |
| Ami Fadia | Needham | Raises | Buy | $130.00 | $97.00 |
| Ami Fadia | Needham | Maintains | Buy | $97.00 | $97.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $125.00 | $125.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $110.00 | $110.00 |
| Ami Fadia | Needham | Maintains | Buy | $97.00 | $97.00 |
| Bradley Canino | Stifel | Raises | Buy | $130.00 | $120.00 |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $114.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Blueprint Medicines compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Blueprint Medicines's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Blueprint Medicines's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Blueprint Medicines analyst ratings.
All You Need to Know About Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
A Deep Dive into Blueprint Medicines's Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Blueprint Medicines's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.87% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Blueprint Medicines's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 92.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE stands out, surpassing industry averages. With an impressive ROE of 40.4%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Blueprint Medicines's ROA excels beyond industry benchmarks, reaching 8.54%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.